Details of the Drug

General Information of Drug (ID: DMSVOZT)

Drug Name
Nifedipine
Synonyms
Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 346.3
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 25 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 10 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The total body clearance of drug is 450-700 mL/min [5]
Elimination
Nifedipine is 60-80% recovered in the urine as inactive water soluble metabolites, and the rest is eliminated in the feces as metabolites [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [5]
Metabolism
The drug is metabolized via the CYP3A4 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.7123 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.044% [9]
Vd
The volume of distribution (Vd) of drug is 0.62-0.77 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.006 mg/mL [4]
Chemical Identifiers
Formula
C17H18N2O6
IUPAC Name
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
InChIKey
HYIMSNHJOBLJNT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4485
ChEBI ID
CHEBI:7565
CAS Number
21829-25-4
DrugBank ID
DB01115
TTD ID
D04OSE
VARIDT ID
DR00396
INTEDE ID
DR1152
ACDINA ID
D00467

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated L-type calcium channel (L-CaC) TTXHYV6 NOUNIPROTAC Modulator [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [15]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Substrate [16], [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nifedipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Pioglitazone DMKJ485 Minor Altered absorption of Nifedipine caused by Pioglitazone. Acute diabete complication [5A2Y] [70]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Nifedipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [71]
Midostaurin DMI6E0R Moderate Decreased metabolism of Nifedipine caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [72]
Idarubicin DMM0XGL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [73]
Arn-509 DMT81LZ Major Increased metabolism of Nifedipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [74]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [75]
Emapalumab DMZG5WL Moderate Altered metabolism of Nifedipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [75]
Siltuximab DMGEATB Moderate Altered metabolism of Nifedipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [75]
Cilostazol DMZMSCT Moderate Decreased metabolism of Nifedipine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [76]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nifedipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [77]
Budesonide DMJIBAW Moderate Decreased metabolism of Nifedipine caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [78]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nifedipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [79]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Nifedipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [80]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Nifedipine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [80]
Cariprazine DMJYDVK Moderate Decreased metabolism of Nifedipine caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [81]
Erdafitinib DMI782S Moderate Increased metabolism of Nifedipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [82]
Pexidartinib DMS2J0Z Major Decreased metabolism of Nifedipine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [83]
Talazoparib DM1KS78 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [84]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Nifedipine caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [85]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nifedipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [86]
Tucatinib DMBESUA Moderate Decreased metabolism of Nifedipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [87]
Palbociclib DMD7L94 Moderate Decreased metabolism of Nifedipine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Nifedipine caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [88]
Bosutinib DMTI8YE Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [75]
Macitentan DMP79A1 Moderate Decreased metabolism of Nifedipine caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [89]
PF-04449913 DMSB068 Moderate Decreased metabolism of Nifedipine caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [90]
Indacaterol DMQJHR7 Minor Decreased clearance of Nifedipine due to the transporter inhibition by Indacaterol. Chronic obstructive pulmonary disease [CA22] [91]
Fidaxomicin DMFP6MV Minor Decreased clearance of Nifedipine due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [92]
Intedanib DMSTA36 Moderate Decreased metabolism of Nifedipine caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [93]
Ulipristal DMBNI20 Minor Decreased metabolism of Nifedipine caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [75]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Nifedipine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [75]
Lumacaftor DMCLWDJ Major Increased metabolism of Nifedipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [74]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nifedipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [94]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nifedipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [95]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [96]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Nifedipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [97]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Nifedipine and Isocarboxazid. Depression [6A70-6A7Z] [98]
Escitalopram DMFK9HG Minor Decreased metabolism of Nifedipine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [99]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nifedipine and OPC-34712. Depression [6A70-6A7Z] [100]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Nifedipine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [101]
Cenobamate DMGOVHA Moderate Increased metabolism of Nifedipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nifedipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Fosphenytoin DMOX3LB Major Increased metabolism of Nifedipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [74]
Rufinamide DMWE60C Moderate Increased metabolism of Nifedipine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Phenobarbital DMXZOCG Major Increased metabolism of Nifedipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [74]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Nifedipine and Nadolol. Essential hypertension [BA00] [103]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nifedipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [104]
Solifenacin DMG592Q Moderate Decreased metabolism of Nifedipine caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [105]
Mirabegron DMS1GYT Minor Decreased metabolism of Nifedipine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [106]
Ripretinib DM958QB Moderate Decreased metabolism of Nifedipine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [92]
Avapritinib DMK2GZX Moderate Decreased metabolism of Nifedipine caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [75]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Nifedipine and Metipranolol. Glaucoma [9C61] [107]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Nifedipine and Levobetaxolol. Glaucoma [9C61] [107]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Nifedipine and Levobunolol. Glaucoma [9C61] [107]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Nifedipine and Carvedilol. Heart failure [BD10-BD1Z] [103]
Boceprevir DMBSHMF Moderate Decreased metabolism of Nifedipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [108]
Simeprevir DMLUA9D Moderate Decreased metabolism of Nifedipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [109]
Telaprevir DMMRV29 Moderate Decreased metabolism of Nifedipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [108]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Nifedipine caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [92]
Rifapentine DMCHV4I Major Increased metabolism of Nifedipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [74]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Nifedipine and Procarbazine. Hodgkin lymphoma [2B30] [98]
MK-1439 DM215WE Minor Decreased metabolism of Nifedipine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Nifedipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [111]
Cobicistat DM6L4H2 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [112]
Dolutegravir DMCZGRE Minor Decreased metabolism of Nifedipine caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [113]
Saquinavir DMG814N Moderate Decreased metabolism of Nifedipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [114]
Etravirine DMGV8QU Moderate Increased metabolism of Nifedipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [115]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Nifedipine caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Darunavir DMN3GCH Moderate Decreased metabolism of Nifedipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Maraviroc DMTL94F Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [117]
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Nifedipine and Acebutolol. Hypertension [BA00-BA04] [103]
Aliskiren DM1BV7W Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [118]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Nifedipine and Penbutolol. Hypertension [BA00-BA04] [103]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Nifedipine and Nebivolol. Hypertension [BA00-BA04] [103]
Tolvaptan DMIWFRL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [119]
Retapamulin DM9JXB7 Minor Decreased metabolism of Nifedipine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [120]
Lesinurad DMUR64T Moderate Increased metabolism of Nifedipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [121]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Nifedipine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [92]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nifedipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [122]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Nifedipine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [123]
Naloxegol DML0B41 Minor Decreased clearance of Nifedipine due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [124]
Pemigatinib DM819JF Moderate Decreased metabolism of Nifedipine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [75]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nifedipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [125]
Osimertinib DMRJLAT Moderate Decreased metabolism of Nifedipine caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [126]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nifedipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Idelalisib DM602WT Moderate Decreased metabolism of Nifedipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [127]
GDC-0199 DMH0QKA Major Decreased metabolism of Nifedipine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [92]
IPI-145 DMWA24P Moderate Decreased metabolism of Nifedipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [128]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Nifedipine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [129]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Nifedipine caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [130]
Arry-162 DM1P6FR Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Arry-162. Melanoma [2C30] [92]
Selumetinib DMC7W6R Moderate Decreased metabolism of Nifedipine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [131]
LGX818 DMNQXV8 Moderate Increased metabolism of Nifedipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [132]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nifedipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [75]
Ubrogepant DM749I3 Moderate Decreased metabolism of Nifedipine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [133]
Exjade DMHPRWG Moderate Decreased metabolism of Nifedipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [134]
Flibanserin DM70DTN Moderate Decreased metabolism of Nifedipine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [135]
Panobinostat DM58WKG Moderate Decreased metabolism of Nifedipine caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [136]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Nifedipine and Siponimod. Multiple sclerosis [8A40] [92]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Nifedipine and Fingolimod. Multiple sclerosis [8A40] [137]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Nifedipine and Ozanimod. Multiple sclerosis [8A40] [138]
Romidepsin DMT5GNL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [139]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nifedipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [75]
Nilotinib DM7HXWT Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [140]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Nifedipine caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [75]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nifedipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [141]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nifedipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [142]
S-297995 DM26IH8 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [75]
Olaparib DM8QB1D Moderate Decreased metabolism of Nifedipine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [143]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nifedipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [144]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Nifedipine and Safinamide. Parkinsonism [8A00] [98]
Istradefylline DM20VSK Moderate Decreased metabolism of Nifedipine caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [145]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Nifedipine and Rasagiline. Parkinsonism [8A00] [98]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Nifedipine caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [146]
Abametapir DM2RX0I Moderate Decreased metabolism of Nifedipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [147]
Lefamulin DME6G97 Moderate Decreased metabolism of Nifedipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [148]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Nifedipine caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [149]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nifedipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [150]
Enzalutamide DMGL19D Major Increased metabolism of Nifedipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [74]
Darolutamide DMV7YFT Minor Decreased clearance of Nifedipine due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [151]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Nifedipine caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [152]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Nifedipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [75]
Ixekizumab DMXW92T Moderate Altered metabolism of Nifedipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [75]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Nifedipine and Levomepromazine. Psychotic disorder [6A20-6A25] [100]
Axitinib DMGVH6N Moderate Decreased metabolism of Nifedipine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [75]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Nifedipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [153]
Upadacitinib DM32B5U Moderate Decreased metabolism of Nifedipine caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [154]
Tocilizumab DM7J6OR Moderate Altered metabolism of Nifedipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [75]
Canakinumab DM8HLO5 Moderate Altered metabolism of Nifedipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [75]
Rilonacept DMGLUQS Moderate Altered metabolism of Nifedipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [75]
Golimumab DMHZV7X Moderate Altered metabolism of Nifedipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [75]
Sarilumab DMOGNXY Moderate Altered metabolism of Nifedipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [75]
Quetiapine DM1N62C Moderate Decreased metabolism of Nifedipine caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [155]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Nifedipine and Aripiprazole. Schizophrenia [6A20] [100]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nifedipine and Iloperidone. Schizophrenia [6A20] [100]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Nifedipine and Paliperidone. Schizophrenia [6A20] [100]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Nifedipine and Molindone. Schizophrenia [6A20] [100]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Nifedipine and Thiothixene. Schizophrenia [6A20] [100]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Nifedipine and Amisulpride. Schizophrenia [6A20] [100]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nifedipine and Asenapine. Schizophrenia [6A20] [100]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nifedipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [156]
LDE225 DMM9F25 Moderate Decreased metabolism of Nifedipine caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [157]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nifedipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [75]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nifedipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [92]
Docetaxel DMDI269 Moderate Decreased metabolism of Nifedipine caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [158]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Nifedipine caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [75]
Armodafinil DMGB035 Moderate Increased metabolism of Nifedipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [92]
LEE011 DMMX75K Moderate Decreased metabolism of Nifedipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [92]
Taxol DMUOT9V Moderate Decreased metabolism of Nifedipine caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [159]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nifedipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [75]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Nifedipine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [160]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [144]
Apixaban DM89JLN Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [75]
Saxagliptin DMGXENV Moderate Decreased metabolism of Nifedipine caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [75]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Nifedipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [161]
Betrixaban DM2C4RF Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [162]
⏷ Show the Full List of 156 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
Ethyl acrylate E00191 8821 Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Menthol E00050 1254 Flavoring agent
methylparaben E00149 7456 Antimicrobial preservative
Potassium chloride E00074 4873 Tonicity agent
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric trioxide E00437 518696 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Isobutyl alcohol E00130 6560 Flavoring agent; Solvent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Methyl methacrylate E00133 6658 Film/membrane-forming agent
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 43 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nifedipine 10 mg capsule 10 mg Oral Capsule Oral
Nifedipine 60 mg tablet 60 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 20 mg capsule 20 mg Oral Capsule Oral
Nifedipine 90 mg tablet 90 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 60 mg tablet 60 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 90 mg tablet 90 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg 24 HR Extended Release Tablet Oral
Nifedipine 60 mg tablet 60 mg 24 HR Extended Release Tablet Oral
Nifedipine 90 mg tablet 90 mg 24 HR Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2514).
2 Are sildenafil and theophylline effective in the prevention of high-altitude pulmonary edema Med Hypotheses. 2002 Aug;59(2):223-5.
3 van Harten J, Burggraaf K, Danhof M, van Brummelen P, Breimer DD: Negligible sublingual absorption of nifedipine. Lancet. 1987 Dec 12;2(8572):1363-5. doi: 10.1016/s0140-6736(87)91258-x.
4 BDDCS applied to over 900 drugs
5 Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am J Med. 1987 Dec 21;83(6B):10-4. doi: 10.1016/0002-9343(87)90630-9.
6 FDA Approved Drug Products: Procardia XL Nifedipine Oral Extended Release Tablets
7 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008 Feb;36(2):386-99. doi: 10.1124/dmd.107.019083. Epub 2007 Nov 15.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12 Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
13 Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
14 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
15 In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
16 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
17 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
28 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
29 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
30 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
31 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
32 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
33 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
34 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
35 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
36 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
45 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
46 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
47 Drug Interactions Flockhart Table
48 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
49 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
50 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
51 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
52 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
53 Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
54 acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
55 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
56 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
57 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
58 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
59 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
60 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
61 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
62 Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
63 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
64 Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
65 N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
66 Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
67 Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
68 Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
69 Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8.
70 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
71 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
72 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
73 Multum Information Services, Inc. Expert Review Panel.
74 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
75 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
76 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
77 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
78 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
79 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
80 Geronimo-Pardo M, Cuartero-Del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R "Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock." Ann Pharmacother 39 (2005): 538-42. [PMID: 15703161]
81 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
82 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
83 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
84 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
85 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
86 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
87 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
88 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
89 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
90 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
92 Cerner Multum, Inc. "Australian Product Information.".
93 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
94 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
95 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
96 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
97 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
98 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
99 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
100 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
101 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
102 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
103 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
104 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
105 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
106 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
107 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
108 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
109 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
110 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
111 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
112 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
113 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
114 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
115 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
116 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
117 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
118 Canadian Pharmacists Association.
119 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
120 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
121 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
122 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
123 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
124 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
125 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
126 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
127 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
128 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
129 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
130 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
131 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
132 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
133 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
134 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
135 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
136 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
137 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
138 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
139 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
140 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
141 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
142 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
143 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
144 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
145 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
146 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
147 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
148 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
149 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
150 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
151 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
152 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
153 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
154 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
155 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
156 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
157 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
158 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
159 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
160 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
161 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
162 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.